Compare Bristol-Myers Squibb Co (BMY) vs Global X Lithium & Battery Tech ETF (LIT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Global X Lithium & Battery Tech ETF — how do they compare? Bristol-Myers Squibb Co trades at $57 (market cap $116.30B), while Global X Lithium & Battery Tech ETF trades at $71.22. The key difference: Bristol-Myers Squibb Co pays a 4.42% dividend while Global X Lithium & Battery Tech ETF pays none, and Bristol-Myers Squibb Co is trading nearer its 52-week high, Global X Lithium & Battery Tech ETF nearer its low. Which is the better fit depends on your goals.
| BMY | LIT | |
|---|---|---|
Market Cap | $116.30B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $62.37 | $91.62 |
52-Week Low | $42.60 | $39.73 |
Enterprise Value | $152.24B | — |
Dividend Yield | 4.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
LIT trades at $70.24, down 2.88% today amid bearish technical signals, with moving averages indicating selling pressure. The stock has doubled over the past year, driven by strong EV and semiconductor demand. Recent news highlights global EV sales growth, particularly in Europe and China, supporting the lithium and battery technology sector. A dividend of $0.32 is scheduled for July 2026.
Outlook remains positive due to structural demand for lithium in energy storage and EVs, though risks include Chinese export controls and U.S. regulatory uncertainty. Analyst sentiment is mixed, with some highlighting momentum catalysts while technical indicators suggest near-term caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Global X Lithium & Battery Tech ETF
LIT invests in the full lithium cycle, from mining and refining to battery production and EV manufacturing. It tracks the Solactive Global Lithium Index, with top holdings including Rio Tinto, Albemarle, and Tesla, as well as major battery makers like Samsung SDI.
Read more on LIT →
